Axsome Therapeutics, Inc. (AXSM) Receives Average Rating of “Strong Buy” from Brokerages

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) have earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price target of $20.33 for the company, according to Zacks. Zacks has also assigned Axsome Therapeutics an industry rank of 138 out of 265 based on the ratings given to related companies.

Several research analysts have recently weighed in on AXSM shares. Cantor Fitzgerald set a $13.00 price objective on Axsome Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 11th. Zacks Investment Research raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 19th.

ILLEGAL ACTIVITY WARNING: “Axsome Therapeutics, Inc. (AXSM) Receives Average Rating of “Strong Buy” from Brokerages” was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be viewed at http://sleekmoney.com/axsome-therapeutics-inc-axsm-receives-average-rating-of-strong-buy-from-brokerages/1657157.html.

Institutional investors have recently added to or reduced their stakes in the stock. State Street Corp increased its position in Axsome Therapeutics by 6.7% in the fourth quarter. State Street Corp now owns 134,688 shares of the company’s stock worth $908,000 after buying an additional 8,466 shares during the period. Baldwin Brothers Inc. MA bought a new position in Axsome Therapeutics during the third quarter worth about $119,000. JPMorgan Chase & Co. increased its position in Axsome Therapeutics by 0.7% in the third quarter. JPMorgan Chase & Co. now owns 1,592,856 shares of the company’s stock worth $12,552,000 after buying an additional 10,625 shares during the period. Schwab Charles Investment Management Inc. bought a new position in Axsome Therapeutics during the second quarter worth about $134,000. Finally, Lombard Odier Asset Management USA Corp increased its position in Axsome Therapeutics by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 341,790 shares of the company’s stock worth $2,577,000 after buying an additional 9,400 shares during the period. Institutional investors and hedge funds own 32.97% of the company’s stock.

Axsome Therapeutics (NASDAQ:AXSM) opened at 4.55 on Friday. The firm’s market capitalization is $87.15 million. The company’s 50-day moving average price is $5.43 and its 200 day moving average price is $6.82. Axsome Therapeutics has a 12 month low of $4.25 and a 12 month high of $12.69.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

5 Day Chart for NASDAQ:AXSM

Get a free copy of the Zacks research report on Axsome Therapeutics (AXSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/axsome-therapeutics-inc-axsm-receives-average-rating-of-strong-buy-from-brokerages/1657157.html

Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *